Frontlight ResearchEarly access
Enrolling by invitationNo phase
Studies brain imaging and tissue in several rare neurodegenerative disorders
Studies brain scans and genetics in people with symptoms suggesting a neurodegenerative disease.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Rochester, United StatesSee the site
- Trial code
- Registry title
- Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders
- Status
- Enrolling by invitation
- People taking part
- 500 people, planned
- Started
- 1 Nov 2020
- Expected to end
- Nov 2050
- Type of study
- Observational
- Treatments tested
- C-11 PiB
- AV1451 Tau
- C-11 ER176
- Record updated
- 21 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults over 21 who have symptoms that may point to a brain disease that gets worse over time (neurodegenerative disorder).
- Age
- Over 21 years
- Sex
- All sexes
- Disease stage
- Symptoms that suggest a neurodegenerative or related disorder
Main reasons for not taking part
- Another illness that could explain all the symptoms, such as brain injury, encephalitis, stroke or developmental syndromes
- Pregnant, or after birth and breast-feeding
- Certain genetic conditions that raise cancer risk, including Down's syndrome
- MRI not possible (for example metal in the head or a pacemaker) or severe claustrophobia
- Medically unstable, or taking medicines that might affect the brain, such as chemotherapy
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- All participants will be over the age of 21
- Have symptoms suggestive of a neurodegenerative and/or related disorder
Who cannot take part
- Participants will be excluded if they have any concurrent illnesses that could account for all of their symptoms, such as traumatic brain injury, encephalitis, strokes or developmental syndromes
- Participants will be excluded if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g. chemotherapy)
- Participants will be excluded if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, Hypogammaglobulinemia, Wiskott-Aldrich syndrome and Down's syndrome
- Participants will be excluded if MRI is contraindicated (metal in head, cardiac pace maker, etc), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma, intracranial neoplasm or large cortical infarcts)
- Women that are pregnant or post-partum and breast-feeding will be excluded
Where in United States
- Mayo ClinicRochester, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
The investigators aim to learn more about symptoms suggestive of a neurodegenerative process.
The group in the trial
- Neurodegenerative symptoms
Treatment: C-11 PiB, AV1451 Tau, and C-11 ER176
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders
- Plain-language title
- Studies brain imaging and tissue in several rare neurodegenerative disordersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 21 November 2025